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nisolone therapy lasted for an average of 3.6 months and a 
complete long-lasting response was achieved in 35 of 42 AIU 
patients (83.3%). The follow-up period was at least 36 months 
(3 years) for each AIU patient; the longest follow-up time was 
139 months (11.5 years). None of the patients reported any 
considerable side effects. Conclusion: Based on our results, 
we suggest that the use of this treatment could be an alter-
native for the treatment of AIU. Our present results also high-
light the need for other therapies in a small percentage of 
AIU patients. Our results suggest that AIU represents a tran-
sient autoimmunity that can be successfully treated with 
low-dose steroid therapy administered for a few months.
© 2018 S. Karger AG, Basel
Introduction
Chronic spontaneous urticaria (CSU) has an estimat-
ed prevalence of 0.5–1.8%. CSU is defined as symptoms 
of urticaria usually occurring daily and persisting for 6 
weeks or more. In some patients, dermographism or ur-
ticaria factitia can also be detected. Patients with urticar-
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Abstract
Background: Chronic spontaneous urticaria (CSU) is defined 
as symptoms of urticaria persisting for 6 weeks or more with-
out obvious cause. Autologous serum skin test (ASST) posi-
tivity in patients with CSU is considered to be associated with 
autoimmune urticaria (AIU). Methods: In this retrospective 
study we retrieved the medical records of 1,073 urticaria pa-
tients seen at the Department of Dermatology and Allergol-
ogy of Szeged University between January 2005 and Febru-
ary 2014. Forty-two patients (36 female and 6 male) met the 
study criteria by having CSU and giving positive results in the 
ASST. Our aim was to assess the clinical efficacy and safety of 
low-dose oral prednisolone therapy administered to pa-
tients with antihistamine-refractory ASST-positive CSU for a 
few months. Patients were given an initial dose (40 mg/day) 
of prednisolone until the complete resolution of the symp-
toms, usually 7–10 days, and then the dose was gradually 
decreased, as in other autoimmune diseases. Results: Pred-
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ia may experience concomitant angioedema and inten-
sive itching. Characteristic wheals last for no more than 
24 h. The term “chronic spontaneous urticaria” is rela-
tively new, as chronic urticaria has recently been divided 
into two main groups: “chronic spontaneous urticaria” 
(CSU) and “chronic inducible urticaria,” the latter in-
cluding the previously termed “physical urticaria” [1, 2]. 
A concomitant autoimmune mechanism can be detected 
in 30–50% of CSU patients. Autoimmune urticaria (AIU) 
is not a well-defined condition, but based on some evi-
dence it is accepted that some CSU patients have anti-IgG 
antibodies against the alpha chain of the high-affinity IgE 
receptor (FcƐRI) on mast cells and basophil granulocytes 
and/or against IgE [3–7]. 
The autologous serum skin test (ASST), an in vivo cu-
taneous test, is based on intradermal injections of small 
quantities of autologous serum. It was first described in 
1986 as a diagnostic tool for chronic idiopathic urticaria 
CIU [8–10]. ASST has been widely adopted internation-
ally as a clinical screening method to assess autoreactivity 
in CSU. In the latest EAACI/GA2 LEN/EDF/WAO (2014) 
guideline, nonsedating H1 antihistamines at the conven-
tional dose is recommended as first-line therapy for CSU, 
and as second-line therapy it is advised to raise the dose 
up to 4 times in nonresponding urticaria patients [1, 11]. 
If patients are unresponsive to both first- and second-line 
treatment, the administration of other systemic therapies 
could be initiated, including azathioprine, leukotriene an- 
tagonists, cyclosporine A and/or mycophenolate mofetil, 
dapsone, TNF-α inhibitors, plasmapheresis, intravenous 
immunoglobulin, and omalizumab. 
In this latest guideline systemic steroid therapy is only 
recommended for a few days, when patients experience a 
severe flare. Flares are frequent among CIU patients, 
therefore these patients often take steroids regularly on an 
on-off basis, without long-lasting therapeutic effect. Kap-
lan [2, 12] recommended a longer course of prednisolone 
therapy for chronic idiopathic urticaria (CIU) patients 
who were unresponsive to antihistamines. Kaplan treated 
patients with 40 mg/day prednisolone for the first 3 days 
and then decreased the prednisolone dosage by 5 mg/day 
gradually, according to the symptoms; when the dosage 
was down to 25 mg/day, it was further decreased by 5 mg 
on alternate days. The steroid then was slowly withdrawn 
by decreasing the dose by 5 mg every 2–3 weeks. In his 
experience a 3-month course of such prednisolone ther-
apy was sufficient for healing the patients. Given the au-
toimmune nature of ASST-positive CSU, we followed the 
recommendation of Kaplan and used a prolonged course 
of low-dose oral prednisolone therapy in AIU patients.
The aim of this retrospective study was to assess the 
efficacy and safety of this therapeutic approach in pa-
tients with ASST-positive CSU.
Patients with urticaria
(n = 1,073)
between 2005 and 2014 at our clinic
Pseudoallergic diet
Exclusion of allergy and focal infections
Antihistamine therapy at conventional dose, then at increased doses
42 antihistamine nonresponders
Autologous serum skin test (ASST): positive
Autoimmune urticaria (AIU)
42 AIU patients treated with oral prednisolone: starting dose at 40 mg/day
for 7–10 days, then dose reduction by 10 mg depending on the patient’s symptoms 
+ calcium, vitamin D3, and H2 blockers 
Fig. 1. Flowchart of Methods.
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Methods
For further details, see the supplementary material (see www.
karger.com/doi/10.1159/000484085 for all online suppl. material) 
[1] (Fig. 1).
Results
Our 42 AIU patients had symptoms (urticaria, itching, 
and/or angioedema) for many years and about 1/3 of 
them have experienced factitious urticaria. Thirty-six of 
the patients included were women (85.71%) and 6 were 
men (14.28%). The mean age at diagnosis was 54 years 
(26–87 years; median: 56.51 years). In 11 of the 42 pa-
tients, anti-thyroglobulin and anti-thyroid peroxidase 
antibodies were also detected. AIU was associated with 
urticaria factitia in 12 of the 42 patients. All concomitant 
diseases of the patients are listed in Table 1. The majority 
of the patients had had treatment for various types of in-
fections (otorhinolaryngological, dental, urological, gy-
necological, and Helicobacter pylori infection) during the 
previous course of their disease. 
Out of the 42 patients, 35 (83.3%) became free of symp-
toms after the initiation of steroid treatment and their 
therapy lasted for an average of 3.6 months (1–13 months; 
Fig. 2). The absolute mean daily dosage was 22.06 mg/day 
for the responding 35 patients (for patients who took the 
steroid for less than 4 months it was 0.34 mg/kg and for 
those who needed longer treatment it was 0.20 mg/kg). 
The mean daily dosage for the 35 patients was 0.32 mg/kg. 
None of these 35 patients relapsed during follow-up 
(Fig. 2); thus among these patients a complete long-lasting 
clinical remission was achieved. Among the 7 nonre-
sponder patients, some partially responded to the therapy, 
but they never became completely symptom free. We de-
tected no difference in terms of concomitant diseases be-
tween the two groups, responders versus nonresponders 
(Table 1). The follow-up of the patients after the end of the 
prednisolone therapy covered a period from 3 to 11.5 
years (Fig. 2); In this group of patients we had no serious 
adverse events; however, 4 patients experienced transi-
tional hair loss and 3 patients gained weight [13].
Discussion
Patients with CSU may suffer from stigmatization due 
to their skin lesions (wheals, excoriations due to itching, 
and angioedema) and the disease often causes consider-
able aesthetic and psychological problems. Various thera-
peutic modalities have been attempted with the aim of 
improving symptoms of CSU with differing degrees of 
success, e.g., first- and second-generation antihistamines, 
leukotriene antagonists, corticosteroids, hydroxychloro-
quine, dapsone, colchicine, sulfasalazine, cyclosporine, 
and omalizumab [1]. In everyday practice one of the most 
common drugs used to treat severe CSU are corticoste-
roids, although current guidelines do not recommend 
steroid therapy for prolonged periods of time since its 
Table 1. Concomitant other diseases in the 42 autoimmune urti-
caria patients
Patient
sex/age,
years
Concomitant diseases
Responders (n=35)
F/83 Vitiligo, polyarthritis
F/42 Hypothyreosis, urticaria factitia disease (UFD)
M/51 Helicobacter pylori infection, UFD
F/75 H. pylori infection
F/62 Polyarthritis, Hashimoto thyroiditis,  
Norwalk infection
F/58 Colon diverticulosis, UFD
F/65 Hypothyreosis
F/57 Hashimoto thyroiditis, rheumatoid arthritis, UFD
M/55 H. pylori infection, UFD
F/75 Hashimoto thyroiditis
F/60 Salmonella infection, morphea
F/56 Myelodysplastic syndrome, anemia with  
vitamin B12 deficiency, irritable bowel syndrome, 
Hashimoto thyroiditis
F/87 Parkinson disease
M/40 UFD
F/43 Hashimoto thyroiditis, UFD
F/51 UFD
M/57 H. pylori infection 
F/26 Hypothyreosis
F/52 Hashimoto thyroiditis
F/38 UFD
F/32 UFD
F/66 Hashimoto thyroiditis
F/68 Hypothyreosis
F/66 Hashimoto thyroiditis
Nonresponders (n = 7)
F/50 Hashimoto thyroiditis
F/40 Hypothyreosis, UFD
F/40 Asthma allergica
F/52 Hashimoto thyroiditis
F/38 UFD
F/52 Hashimoto thyroiditis
F/66 H. pylori infection
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side effects could be considerable (hypertension, osteo-
porosis, cutaneous striae, obesity, cataract, diabetes, etc.). 
In 1986 Grattan et al. [8] identified AIU among patients 
with CSU, termed at the time CIU. Many case reports de-
scribed the rapid efficacy of steroid therapy in AIU, but 
no complete and long-lasting response has been reported 
on prednisolone treatment. The EAACI/GA2 LEN/EDF/
WAO guidelines have discouraged the long-term use of 
oral corticosteroids in chronic urticaria, although evi-
dence for this recommendation was lacking [1].
Systemic corticosteroids can exert influence on mul-
tiple levels: they suppress antibody formation, have a 
strong anti-inflammatory effect, and decrease the pro-
duction of histamine-releasing factors. AIU is character-
ized by IgG antibodies against the alpha chain of the high-
affinity IgE receptor (FcƐRI) on mast cells and basophil 
granulocytes and/or by antibodies directed against IgE 
antibodies. These antibodies play a role in mast cell and 
basophil activation and in the release of both preformed 
and newly generated mediators (chemokines, cytokines, 
histamine, serotonin, and leukotrienes) [5, 7, 11, 14]. The 
“gold standard” in vitro methods in AIU detect serum-
induced histamine release in basophils (HR assay) and 
CD63 expression on basophils and mast cells [15–17]. 
Laboratory tests with high specificity and sensitivity are 
required for screening patients to detect circulating func-
tional autoantibodies and thereby unequivocally diag-
nosing AIU among CSU patients. Recently, Lee et al. [18] 
developed a rapid immunodot method with high specific-
ity to detect autoantibodies against the FcƐRIα chain in 
the sera of CSU patients. Unfortunately, these tests are 
not available yet in everyday clinical practice. Presently, 
the ASST is used in clinical practice to detect AIU. In 
AIU, the incidence of anti-thyroid antibodies is higher, 
and patients should be screened for anti-thyroid peroxi-
dase and anti-thyroglobulin antibodies [19].
Because it has been demonstrated that ASST with un-
diluted serum could result in nonspecific positive reac-
tions, Husz et al. [20] suggested the use of 1: 10 and 1: 100 
serum dilutions in order to avoid nonspecific test reac-
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Fig. 2. The length of steroid therapy and the length of follow-up symptom-free period after cessation of therapy 
for recovered autoimmune urticaria patients (n = 35).
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tions. In a follow-up study the same workgroup com-
pared the dilution ASST with the CD63 expression test 
and concluded that dilution did not improve the specific-
ity of the test. However, the severity of AIU correlated 
well with positive reactions at diluted serum, and there-
fore it was suggested that using different dilutions of the 
serum in ASST might serve as a useful indicator of disease 
severity [21]. The detected autoreactivity, however, does 
not directly prove the presence of autoantibodies.
Szegedi and colleagues [22] suggested complementing 
the ASST results with characteristic clinical signs to im-
prove the diagnosis of AIU. The sensitivity (88%) and 
specificity (77%) of ASST complemented with simultane-
ous clinical symptoms (wheals 6–7 times a week, angio-
edema and anti-thyroid antibodies) considerably in-
creased the sensitivity (up to 94%) and specificity (up to 
86%) of this test. 
To our knowledge this is the first report on the use of 
this few-months-long low-dose oral corticosteroid thera-
py in a larger AIU study group. The prolonged (average 
3.6 months) immunosuppressive therapy proved to be 
safe and effective in improving the symptoms of patients 
with positive ASST. Only a few patients experienced light 
transitional adverse effects during treatment. The circu-
lating autoantibodies responsible for the autoreactive 
mechanisms in AIU may not be long-lasting and a pro-
longed oral prednisolone therapy seems to restore the 
normal balance of the immune system. Although sponta-
neous remission is possible, these patients suffer from 
their symptoms and they need treatment. Based on our 
results, we consider that prolonged administration of 
low-dose oral corticosteroids can be a valuable therapeu-
tic alternative in patients with therapy-resistant AIU ur-
ticaria. However, our results have also highlighted the 
need for other therapeutic approaches (e.g., omalizumab) 
in a small percentage of AIU patients.
Key Message
Low-dose oral corticosteroid therapy administered for a few 
months can treat autoimmune urticaria patients.
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